INCYTE - Dusseldorf Stock Exchang (ICY DU) stock market data APIs
€73.9844
-0.62(-0.8%)
as of October 21, 2025
Try our APIs with
free plan!
INCYTE - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ICY.DU.
Prev. Close
73.9844
Open
73.3671
High
75.2499
Low
73.0001
52 wk Range
48.52-78.06
Market Cap
12 792 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INCYTE - Dusseldorf Stock Exchang data using free add-ons & libraries
Get INCYTE - Dusseldorf Stock Exchang Fundamental Data
INCYTE - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INCYTE - Dusseldorf Stock Exchang News
New
Assessing Incyte’s Share Price After Recent FDA Approval and Strong 2024 Gains
If you've been thinking about what to do with your Incyte shares, or whether now is a smart time to jump in, you’re not alone. The stock has been on the move lately, catching the attention of both c...
Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of ...
Xencor Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Xencor shows improving technical performance. Will it continue? Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
